Michel R.M. Rod Joins United Cannabis Corp Advisory Board

10/03/17 08:30 AM EDT

Author of "Marketing ROI For Pharma" Will Drive Commercialization of Company's Products

DENVER, CO / ACCESSWIRE / October 3, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced that Dr. Michel R.M. Rod has joined the Company's Advisory Board to provide guidance as it seeks to commercialize its patented Prana Bio-Nutrient Medicinal products.

Professor Rod currently serves as Associate Dean Research & International and PhD Program Director at the Sprott School of Business, Carleton University in Ottawa, Canada, where his research focuses on the collaboration amongst pharmaceutical industry, government, and university partners in the health sector.

Dr. Rod received his Bachelor of Science in Pharmacology and Toxicology from the University of Western Ontario, a Master of Science in Medical Sciences from the University of Calgary, and earned his PhD in Marketing at the University of Birmingham, UK. He has also published more than 120 peer-reviewed articles in business and medical journals, and conference proceedings and was the recipient of a multi-year doctoral fellowship from the Institute of Health Economics in Edmonton.

Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement saying, "Michel is another great addition to our team - he literally wrote the book on marketing pharmaceuticals! I am confident that he will be the perfect complement to the doctors, scientists and researchers we already have on board as we begin to navigate this next stage of development."

Commenting on the appointment, Professor Rod added, "United Cannabis is a progressive company that isn't constrained by a quarterly mentality and is clearly in this business for the long-term. Unlike many of its competitors, senior management is assuming a traditional pharmaceutical perspective to the development of its Prana line. That approach is now paying off as the Company plans to commence clinical trials with a patented product. I very much look forward to working with the entire team in their effort to bring their products to market - in the US and around the world."

About United Cannabis Corporation

United Cannabis is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. Our products include supplements, medical cannabis therapeutics, and pharmaceutical drugs.

For further information, please visit www.unitedcannabis.us.

Contact: Staff@UnitedCannabis.us Phone: 303-386-7321

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: United Cannabis Corporation